Genflow Biosciences (LON: GENF) (OTCQB: GENFF) starts trading on the OTCQB market in the US today under that ticker GENFF. The shares in London have risen 9% in reaction. As we noted before about Genflow and this plan a new listing can have this effect. GENF was up 21% on the day it was announced for example.
As we said back then: “The more specific issue today is that OTCQB quotation coming up. There will be no fundraising associated with it. But it does give access, in the future, to American pools of capital. And given the way in which New York is much more used to funding research pharma the pricing will - when that time comes - be much less dilutive. New York's just a better - cheaper - place to raise capital for pharma development than London is. Thus the New York quote can be considered to be value generative.”
This might all sound odd in a world of global investment patterns but it's - once the details are considered - not all that odd.

Genflow Biosciences share price from London Stock Exchange#
American investors just are more used to the usual trading patterns of medical research companies. Have an idea, need some money to test it. OK, here's the money to test this idea. But pharma research has many valuation points. Phase I, II and III testing, subsets of those and so on. To actually get to market something must pass through all of those and gain FDA approval. OK. So what happens is that capital is raised to meet that next test point. If it then fails, well, so be it. If it passes then more capital is raised to try to reach the next test point and so on.
So, research pharma is a constant series of tests and capital raises. This is just something the American markets are more used to. Despite Britain having a good stock of such research companies. So, if there's an American investor bas for such a company they might well find capital cheaper - they're with investors who understand the system.
However, Americans aren't really allowed to buy stock off the American markets - or more accurately, it's not legal to market stock to them unless the SEC has approved. So, have a US quote, which is SEC approved, which builds the American shareholder base which is better suited to the business model.
Of course, this doesn't mean that the research will be successful in itself but it does make the process easier and can quite possibly make capital cheaper to raise. Which is both why this move to the OTC market and also the share price rise in GENF as a result.



